Article

Dr. George Addresses Provider Issues Regarding Immunotherapies

Conference|ASCO: American Society of Clinical Oncology

Daniel George, MD, Director, Prostate Clinic, Genitourinary Oncology, Duke Cancer Institute, specifically discusses the immunotherapy agent, sipuleucel-T (Provenge) used in the treatment of prostate cancer.

Daniel George, MD, Director, Prostate Clinic, Genitourinary Oncology, Duke Cancer Institute, specifically discusses the immunotherapy agent, sipuleucel-T (Provenge) used in the treatment of prostate cancer. He says that when the drug first came on the market many administrative challenges existed. There were limited access and associated reimbursement issues due to the limited production capabilities. However, Dr George states that currently there are no issues with payer coverage with little to no delays when it comes to prescribing the agent.

This video was taken on June 1, 2013, at the ASCO Annual Meeting 2013 in Chicago, IL.

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Subscribe Now!
Related Videos
Andrew Kuykendall, MD, Moffitt Cancer Center
Dr Sundar Jagannath
David J. Maron, MD, FASPC, Stanford University School of Medicine
Karen Vo talks about antibullying campaigns and pediatric patients with derm conditions
Hira Ghani, DO, discusses underdiagnosed skin conditions in children
Rebecca Chacko, MD.
Dr María Díez Campelo
Dr María Díez Campelo
Related Content
ROS1-positive NSCLC is aggressive and rare, with approximately 3000 new diagnoses of advanced disease in the US each year. | Image credit: appledesign - stock.adobe.com
August 1st 2025

Taletrectinib Recommended in NCCN Guidelines for ROS1-Positive NSCLC

Rose McNulty
Taletrectinib was added to the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology as a preferred option for the first-line and subsequent treatment of advanced ROS1-positive non–small cell lung cancer (NSCLC).
Managed Care Cast
August 1st 2025

Navigating Risk, Treatment, and Reimbursement in Precision Oncology: Sadie Dobrozsi, MD

Giuliana Grossi Sadie Dobrozsi, MD, MS Interview by Mary Caffrey
Sadie Dobrozsi, MD, of Evolent, discusses how predictive genomics is pushing cancer care into a new era of personalization
Value-based care. | Image Credit: irissca - stock.adobe.com
August 1st 2025

Legal Navigation Services Key to Addressing Disparities in Cancer Care

Cameron Santoro
A significant number of patients with cancer, caregivers, and health care professionals face significant disparities in legal issues, with the most common needs revolving around health insurance, finances, employment, and disability insurance.
Managed Care Cast Thumbnail
August 1st 2025

Personalized Care Key as Tirzepatide Use Expands Rapidly

Maggie L. Shaw John W. Ostrominski, MD
Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Following an investigation, the FDA confirmed that shipments of delandistrogene moxeparvovec can resume. | Image Credit: immimagery - stock.adobe.com
August 1st 2025

FDA Recommends Sarepta Resume DMD Gene Therapy Shipments for Ambulatory Patients

Rose McNulty
Shipment of delandistrogene moxeparvovec, a gene therapy for Duchenne muscular dystrophy (DMD), will resume following a voluntary pause.
HCC is the most common type of liver cancer, and it typically occurs in patients with chronic liver conditions. | Image Credit: Crystal light - stock.adobe.com
August 1st 2025

TACE Plus SBRT Effective in Large Tumors Caused by HCC

Jared Kaltwasser
TACE combined with SBRT enhanced survival rates in patients with large hepatocellular carcinoma tumors, offering promising treatment insights.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo